Stock Scorecard
Stock Summary for Compugen Ltd (CGEN) - $1.53 as of 12/23/2025 2:48:49 PM EST
Total Score
10 out of 30
Safety Score
16 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CGEN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CGEN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CGEN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CGEN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CGEN (16 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CGEN
Financial Details for CGEN
Company Overview |
|
|---|---|
| Ticker | CGEN |
| Company Name | Compugen Ltd |
| Country | USA |
| Description | Compugen Ltd. (CGEN) is a forward-thinking clinical-stage biotechnology company based in Holon, Israel, specializing in the discovery and development of innovative therapeutics for cancer and autoimmune diseases. Leveraging its cutting-edge computational discovery platform, Compugen is advancing a robust pipeline of immuno-oncology candidates aimed at targeting pivotal pathways within the tumor microenvironment. With a strategic focus on both the U.S. and European markets, the company is poised to disrupt existing treatment paradigms and enhance patient outcomes in oncology and related fields. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/19/2026 |
Stock Price History |
|
| Last Day Price | 1.53 |
| Price 4 Years Ago | 4.30 |
| Last Day Price Updated | 12/23/2025 2:48:49 PM EST |
| Last Day Volume | 336,604 |
| Average Daily Volume | 374,446 |
| 52-Week High | 2.66 |
| 52-Week Low | 1.13 |
| Last Price to 52 Week Low | 35.40% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 70.99 |
| Sector PE | 135.38 |
| 5-Year Average PE | -7.55 |
| Free Cash Flow Ratio | 19.13 |
| Industry Free Cash Flow Ratio | 14.52 |
| Sector Free Cash Flow Ratio | 32.38 |
| Current Ratio Most Recent Quarter | 4.38 |
| Total Cash Per Share | 0.08 |
| Book Value Per Share Most Recent Quarter | 0.47 |
| Price to Book Ratio | 3.24 |
| Industry Price to Book Ratio | 64.08 |
| Sector Price to Book Ratio | 56.98 |
| Price to Sales Ratio Twelve Trailing Months | 20.73 |
| Industry Price to Sales Ratio Twelve Trailing Months | 22.22 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.53 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 93,535,000 |
| Market Capitalization | 143,108,550 |
| Institutional Ownership | 13.66% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.38% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 24.12% |
| Reported EPS 12 Trailing Months | -0.30 |
| Reported EPS Past Year | -0.23 |
| Reported EPS Prior Year | -0.16 |
| Net Income Twelve Trailing Months | -27,619,000 |
| Net Income Past Year | -14,231,000 |
| Net Income Prior Year | -18,754,000 |
| Quarterly Revenue Growth YOY | -89.00% |
| 5-Year Revenue Growth | 13.45% |
| Operating Margin Twelve Trailing Months | -417.40% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,455,000 |
| Total Cash Past Year | 18,229,000 |
| Total Cash Prior Year | 13,890,000 |
| Net Cash Position Most Recent Quarter | 7,455,000 |
| Net Cash Position Past Year | 18,229,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 54,914,000 |
| Total Stockholder Equity Prior Year | 65,559,000 |
| Total Stockholder Equity Most Recent Quarter | 43,826,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 0 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.00 |
| Free Cash Flow Past Year | 49,486,000 |
| Free Cash Flow Prior Year | -36,058,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 2.82 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 1.53 |
| 200-Day SMA | 1.55 |
System |
|
| Modified | 12/22/2025 7:52:09 PM EST |